These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Prevention of congenital rubella in Iceland by antibody screening and immunization of seronegative females. Author: Gudmundsdóttir S, Antonsdóttir A, Gudnadóttir S, Elefsen S, Einarsdóttir B, Olafsson O, Gudnadóttir M. Journal: Bull World Health Organ; 1985; 63(1):83-92. PubMed ID: 3872738. Abstract: A programme to eradicate congenital rubella from Iceland was started in 1979, based on (1) screening of all females aged 12-45 years for rubella antibodies and (2) vaccination of all seronegative persons with the RA/27/3 rubella vaccine, given free of charge. Thus, individual protection was offered to all who needed it. The collection of serum samples was planned to last for 2 years while, simultaneously, the already established rubella screening and immunization programmes for 12-year-old schoolgirls and pregnant women continued.During assessment in 1983, 95.2% of females in the first 7 age groups (by now aged 14-20 years) participating in the school programme had been tested and 80.4% of them were found to be naturally immune. Of the seronegatives, 93.7% were subsequently vaccinated, thus giving an overall immunity rate of 98.8%. Among the women in the peak of the childbearing period (by now aged 21-35 years), 84.4% had been tested and 92.7% were found to be naturally immune; vaccination of 61.4% of seronegative individuals then gave an overall immunity rate of 97.2% for this age group.If it is assumed that the natural immunity rate of females still untested is like that of the above groups, then the percentage of non-immune persons is at present 2.1% in the younger group and 3.4% in the older.[Abstract] [Full Text] [Related] [New Search]